How Does the Immune System Detects Cancer Cells?
June 16, 2026Cancer is not only a story of cells going out of control — it's the immune system's long surrender
—— Tumor immunology: the scientific field that rewrote the rules of cancer treatment.
I. A transformation that overturned a century of understanding
For most of the twentieth century, oncologists primarily understood cancer as a problem of autonomous cellular loss of control: gene mutation → uncontrolled cell proliferation → tumor formation. The treatment logic was to find ways to kill these out-of-control cells — surgical removal, radiation bombardment, chemotherapy toxins. The immune system was basically absent from this framework.
This understanding was completely rewritten over the past thirty years. Growing evidence shows that tumor formation and development isn't just about cancer cells themselves — it's profoundly influenced by immune system status. The immune system isn't a bystander; it's an active participant: sometimes fighting, sometimes co-opted by cancer, sometimes even exploited to help the tumor grow. The most direct evidence comes from organ transplant patients: these people need long-term immunosuppressants to prevent rejection, and the cost is their cancer incidence is several times higher than the general population. When the immune system is artificially suppressed, cancer seizes the opportunity at speeds far exceeding imagination.
2. The origin of tumor immunology: a question debated for a hundred years
The history of tumor immunology is longer and more winding than most people assume. In the 1890s, New York surgeon William Coley noticed something strange: some cancer patients who developed severe bacterial infections after surgery sometimes found their tumors shrink — even disappear — after the infection resolved. Coley proposed that infection had activated some kind of anti-tumor immune response. He began treating tumor patients with dead bacterial mixtures (later called 'Coley's toxins'), achieving some striking results.
But mainstream medicine was highly skeptical — no one could explain the mechanism, and efficacy was inconsistent. As radiation therapy and chemotherapy emerged, Coley's work was gradually marginalized, even mocked as quackery. Not until the second half of the twentieth century, with the advancement of immunological tools, could scientists begin to see at the molecular and cellular level what was actually happening between the immune system and tumors. Coley is now retrospectively regarded as a pioneer of cancer immunotherapy. His core intuition — that activating the immune system can combat tumors — was proven correct a hundred years later, even though he had no idea about the mechanism at the time.
3. 2011: the turning point when tumor immunology truly entered the clinic
If you had to choose a year marking the transition of tumor immunology from laboratory to clinic, most experts would choose 2011. That year, the US FDA approved the first immune checkpoint inhibitor: Ipilimumab (anti-CTLA-4 monoclonal antibody) for treating metastatic melanoma — one of the hardest-to-treat skin cancers, with a median survival after metastasis under one year. Ipilimumab's clinical trial showed significant survival prolongation in some patients; more importantly, a small subset achieved durable complete remission — something previously nearly impossible in metastatic melanoma.
This result proved a long-questioned hypothesis: intervening in the immune system — rather than directly attacking tumor cells — can achieve real, durable anti-tumor effects. In subsequent years, more checkpoint inhibitors (PD-1 inhibitors, PD-L1 inhibitors) were successively approved, with indications rapidly expanding from melanoma to lung cancer, liver cancer, bladder cancer, stomach cancer, esophageal cancer, and dozens of other cancer types. In 2018, James Allison and Tasuku Honjo won the Nobel Prize in Physiology or Medicine for discovering CTLA-4 and PD-1's roles in immune regulation — the highest academic recognition of the entire tumor immunology field.
4. Core participants in tumor immunology
Understanding tumor immunology requires knowing several key players who will reappear throughout the following articles. On the immune system side: NK cells (Natural Killer cells) — the core anti-tumor weapon of innate immunity; can directly recognize and kill cancer cells without prior learning; the immune system's earliest anti-tumor responder. Cytotoxic T cells (CD8+ T cells) — the adaptive immune system's precision killers; need to be 'trained' by antigen-presenting cells, but once activated, can efficiently and specifically clear specific tumor cells. Dendritic cells — present tumor antigens to T cells; the critical hub connecting innate and adaptive immunity. Macrophages — depending on environment, can be the tumor's enemy (M1 type) or co-opted by the tumor as an accomplice (M2 type).
On the tumor side: tumor cells themselves, which produce tumor antigens through gene mutations, and also actively evade immune recognition through various mechanisms. The tumor microenvironment (TME) — the complex ecosystem around the tumor; tumors actively shape this environment, turning it into a 'restricted zone' unfavorable for immune cell activity.
5. Why tumor immunology is currently the hottest cancer research field
Over the past decade, tumor immunology's share of global cancer research funding has grown from marginal to central. This isn't only because it's produced good clinical results — more fundamentally, it represents a completely different treatment logic. Traditional chemotherapy's problem isn't only toxic side effects; more fundamentally, it kills rapidly dividing cells without distinguishing cancer cells from normal fast-dividing cells (like bone marrow hematopoietic cells, intestinal epithelial cells). And cancer cells evolve drug resistance — chemotherapy ultimately faces a moving target.
Immunotherapy's logic differs: it activates the immune system's own precise recognition capacity, theoretically capable of recognizing and clearing cancer cells throughout the body — including already-metastasized lesions — with far less harm to normal cells than chemotherapy. More importantly, immune memory formation means treatment can produce durable effects — something chemotherapy cannot achieve. Of course, immunotherapy also has its limitations: not all cancer types and patients respond; immune-related toxic side effects can be severe; costs remain high. But the direction is right, and progress is real.
6. Tumor immunology's next decade
The success of immune checkpoint inhibitors is only the first chapter of the tumor immunology story. Several most actively researched directions represent this field's next decade: individualized cancer vaccines — sequencing a patient's tumor to find unique mutation-produced neoantigens, then tailoring immune weapons specific to that patient, with mRNA technology making this direction realistically feasible. CAR-T and CAR-NK cell therapies — modifying patients' immune cells outside the body, giving them stronger tumor recognition and killing capacity. Tumor microenvironment remodeling — not only activating the immune system, but simultaneously transforming the 'immune restricted zone' around the tumor so immune cells can get in, survive, and kill. Combination treatment strategies — targeting multiple immune evasion pathways simultaneously to seal off the tumor's escape routes.
7. What tumor immunology's most important insights mean for ordinary people
Tumor immunology isn't only a topic for top laboratories and oncologists. Its core insights have direct practical implications for every person who cares about their health. The immune system's surveillance function is your most important but lowest-profile tumor defense. Maintaining this defense's health is the most practical tumor prevention you can do right now. Adequate sleep, regular exercise, not smoking, maintaining healthy body weight — these aren't vague 'healthy lifestyle' recommendations but tumor prevention strategies with clear immune mechanisms. Sleep deprivation drops NK cell activity by approximately seventy percent in a single night. Long-term physical inactivity lowers immune surveillance efficiency. Smoking not only is a direct carcinogen but is a 'shutdown switch' that systematically weakens immune surveillance.
Understanding tumor immunology helps you more rationally face cancer diagnosis and treatment choices. When a doctor says 'your tumor has high PD-L1 expression, I recommend combined immunotherapy,' you understand what that means. When you see news about 'mRNA cancer vaccine clinical trial,' you can understand the scientific logic behind it.
Frequently Asked Questions